AstraZeneca today announced positive results from a Phase III study comparing the efficacy and safety of dapagliflozin versus placebo as an add-on to saxagliptin and metformin immediate release ...

After 24 weeks, individuals receiving dapagliflozin 2.5 mg, 5 mg and 10 mg plus metformin demonstrated a statistically significant adjusted mean change in HbA1c from baseline of -0.67 percent, -0. ...

The study investigating dapagliflozin 10 mg also demonstrated non-inferiority of dapagliflozin 10 mg plus placebo compared to metformin XR plus placebo in reducing HbA1c (-0.01%, 95% CI -0.22 to 0 ...

The study investigating dapagliflozin 10 mg also demonstrated non-inferiority of dapagliflozin 10 mg plus placebo compared to metformin XR plus placebo in reducing HbA1c (-0.01%, 95% CI -0.22 to 0 ...

Dapagliflozin 10 mg significantly reduced mean systolic blood pressure (-4.8 mm Hg) vs placebo (-1.7 mm Hg) from baseline to week 24 (difference -3.1 mm Hg, p < 0.05).

Moreover, early dapagliflozin initiation was associated with improved: median 24-hour natriuresis (50 vs. 35 mmol/40 mg IV furosemide; P = .025); ...

A phase 3 randomized trial of the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin (Farxiga, AstraZeneca) for chronic heart failure has met its primary composite outcome with a ...

The efficacy analysis reports data on patients who were randomized to three treatment arms evaluating 1) high-dose combination of zibotentan (1.5 mg) and dapagliflozin (10 mg), 2) low-dose ...

Among the 2,906 participants with type 2 diabetes, 1,455 received dapagliflozin and 1,451 received placebo. Of those without type 2 diabetes, 697 received dapagliflozin and 701 received placebo.

Early initiation of dapagliflozin does not appear to interfere with diuretic treatment for heart failure. (HealthDay News) — For patients with acute heart failure (AHF), early initiation of ...